Glioblastoma, the most aggressive and fatal type Brain tumorwhich is known to have a very poor prognosis, but new research suggests that pain relief drugs can expand survival.
Researchers at Mass General Brigham said: Already approved drugs – Pain medicines and antiseizure drugs called gabapentin are associated with improved survival in glioblastoma patients.
The findings were published last week on Nature Communications.
Michael Bolton had strange symptoms before being diagnosed with brain cancer: “Something is wrong”
I was inspired previously Mouse Research It demonstrates the possibility of gadapentin targeting tumors, and researchers have studied medical results in nearly 700 patients with glioblastoma.
According to a press release from MGB, many of them were taking gabapentin to reduce neuralgia.
Glioblastoma, the most aggressive and deadly brain tumor, is known to have a very inadequate prognosis, but new research suggests that pain relief drugs can expand survival. (istock)
Patients taking the drug survived at 16 months compared to those who were referred to as “statistically significant.”
“Ultimately, our goal was to highlight the new role of cancer neuroscience in GBM progression and to highlight the importance of exploring creative strategies to therapeutically target this evolving neurotumor axis,” said lead author Joshua Byrnestock, MD, PHD, clinical fellow at Brig of Neurosurgery and clinical fellow at FOX Digital.
Breast cancer drugs could help prolong survival in children with brain tumors, research finds
The team was surprised by the benefits of survival, Burnstock pointed out.
“It’s always incredible to see hypotheses come to life,” he said. “We were also really pleased to see a decrease in serum TSP-1 levels in the UCSF cohort and could position it as a biomarker of response.”
Painful medications and antiseizure drugs called gabapentin are associated with improved survival in glioblastoma patients. (istock)
Based on the initial findings, Byrnestock contacted researchers at the University of California, San Francisco (UCSF) to study more glioblastoma patients.
The same results were observed out of 379 patients with USCF. Patients taking gabapentin averaged 20.8 months compared to 14.7 months in those not taking the drug.
“Since the early 2000s, there has been little progress in survival rates for GBM patients. ”
“In both cohorts (1,072 patients in total), gabapentin use was consistently associated with statistically significant. Improve survival“Barnstock told Fox News Digital.
Researchers also noticed that the gadapentin group had low levels of a protein called TSP-1. This is found in serum and “more investigation is needed.”
Glioblastoma advocates the lives of approximately 14,500 Americans each year. The 5-year survival rate is only 6.9%. (istock)
“Since the early 2000s, there has been little progress in survival rates for GBM patients,” Byrnestock said in the release. “We need to think more creatively Emerging Biology In these tumors and how to target them. ”
Things you need to know about gadapentin
The US Food and Drug Administration (FDA) first approved gadapentin in December 1993 to treat seizure activity in adults. The approval was extended in 2000 to include children.
Two years later, the agency approved Gadapentin Neuralgia after shinglesaccording to the agency.
The drug is often prescribed for off-label use to treat a variety of pain conditions, studies show.
The drug is often prescribed for off-label use to treat a variety of pain conditions, studies show. (istock)
More common side effects of gadapentin include fatigue, headache, dizziness, fever, nausea and vomiting, memory loss, speaking, weight gain, Vision problemsMovement issues and recurrent infections, according to Cleveland Clinic.
Certain drugs may interact with gadapentin. Patients should talk to their doctor if they are experiencing severe or persistent side effects, experts recommend.
Potential limitations and next steps
This study had several limitations. It is primarily retrospective and uncontrolled.
“The findings are promising, but this study is retrospective. Patients were not administered gabapentin in a controlled, randomized manner to directly assess its effectiveness,” Byrnestock told Fox News Digital.
“So the bigger future Clinical trials These results are necessary to examine and further explore the role of gabapentin and TSP-1 in GBM progression. ”
Click here to sign up for our health newsletter
Byrnestock said he was “cautiously optimistic” by the findings.
“Gabapentin is FDA approved and is generally well tolerated, but it is not appropriate to modify clinical practice based solely on these findings without a control study. UCSF collaborators are working on,” he said.
“It is not appropriate to change clinical practice based solely on these findings without controlled studies.”
“However, there may be a rationale to consider gabapentin more easily than other drugs in GBM patients who develop neuropathic pain or seizures after a negative incision.”
Visit us for more health articles www.foxnews.com/health
Glioblastoma – described by Burnstock as “a merciless, progressive, universally fatal disease” – is the most common type Primary brain cancerAccording to Mayo Clinic.
The disease advocates the lives of around 14,500 Americans each year. The 5-year survival rate is only 6.9%.
